Alzheimer's disease (AD) is a major global public health threat for which we have very limited responses. Solutions will come only though research. The AD Centers (ADC) Program is a leading effort by the US under the responsibility of the National Institute on Aging (NIA) to develop solutions for AD. The central research strategy of NIA is Seeking the Earliest Interventions. The University of Washington (UW) ADC is one of fifteen AD Research Centers (ADRCs), and we contribute uniquely to this premier program through our vision of precision medicine for AD: comprehensive classification of an individual's risk; surveillance with accurate and early detection of patho-physiologic processes while still preclinical; and interventions tailored to an individual's molecular drivers of disease All components of UW ADRC are focused on this vision and our 5-year mission of creating the knowledge and tools needed to advance preclinical biomarkers and develop experimental therapeutics, while also enthusiastically participating in (inter)national collaborations in clinicl trials, AD genetics, brain aging, diagnostics, and outreach to disparities populations. UW ADRC balances stability with innovation. Stability in the leadership of our required Cores assures highest quality outcomes for the ADC Program. Innovation draws on the vast resources of UW to develop three new Projects, a new Satellite Core, and a new component of our Clinical Core to fuel discoveries. UW ADRC resonates strongly with the three principles of National Plan to Address Alzheimer's Disease, especially its third: transform the way we approach AD. Successful completion of our 5-year mission will hasten this transformation to the right intervention for the right person at the right time - precision medicine for AD.

Public Health Relevance

Alzheimer's disease (AD) is the 4th leading cause of death in the US and by far the fastest-increasing cause of US deaths. Currently, there are limited responses to this major public health threat; solutions will come only from research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005136-33
Application #
9088230
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
1997-05-01
Project End
2020-04-30
Budget Start
2016-08-01
Budget End
2017-04-30
Support Year
33
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Washington
Department
Psychiatry
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Turk, Katherine W; Flanagan, Margaret E; Josephson, Samuel et al. (2018) Psychosis in Spinocerebellar Ataxias: a Case Series and Study of Tyrosine Hydroxylase in Substantia Nigra. Cerebellum 17:143-151
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Bharadwaj, Rajnish; Cimino, Patrick J; Flanagan, Margaret E et al. (2018) Application of the condensed protocol for the NIA-AA guidelines for the neuropathological assessment of Alzheimer's disease in an academic clinical practice. Histopathology 72:433-440
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Tulloch, Jessica; Leong, Lesley; Chen, Sunny et al. (2018) APOE DNA methylation is altered in Lewy body dementia. Alzheimers Dement 14:889-894
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 753 publications